반응식
[CH3:1][O:2][CH2:3][C:4]1[CH:9]=[C:8]([C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:16]=[C:17]([CH:21]=[CH:22][CH:23]=3)[C:18](Cl)=[O:19])[N:11]=2)[CH:7]=[CH:6][C:5]=1[C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][C:25]=1[CH3:30].Cl.[CH2:32]([O:34][C:35]([C:37]1([NH2:40])[CH2:39][CH2:38]1)=[O:36])[CH3:33]>>[CH3:1][O:2][CH2:3][C:4]1[CH:9]=[C:8]([C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:16]=[C:17]([CH:21]=[CH:22][CH:23]=3)[C:18]([NH:40][C:37]3([C:35]([O:34][CH2:32][CH3:33])=[O:36])[CH2:39][CH2:38]3)=[O:19])[N:11]=2)[CH:7]=[CH:6][C:5]=1[C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][C:25]=1[CH3:30]참가 물질
반응물 2
생성물 1
실험 절차
The title compound was prepared following procedure described in Example 121 starting from 3-{5-[2-(methoxymethyl)-2′-methylbiphenyl-4-yl]-1,2,4-oxadiazol-3-yl}benzoyl chloride, prepared as in example 130, and 1-aminocyclopropane-1-carboxylic acid ethyl ester hydrochloride. The title compound was obtained as a white foam (120 mg, 98%). 1H NMR: (DMSO-d6, 300 MHz) δ 9.35 (m, 1H), 8.60 (m, 1H), 8.35 (m, 1H), 8.29 (m, 1H), 8.19 (m, 1H), 8.09 (m, 1H), 7.77 (t, J=7.8 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.39-7.26 (m, 3H), 7.15 (m, 1H), 4.23 (d, J=12.9 Hz, 1H), 4.17 (d, J=12.9 Hz, 1H), 4.08 (q, J=7.1 Hz, 2H), 3.25 (s, 3H), 2.04 (s, 3H), 1.47 (m, 2H), 1.21 (m, 1H), 1.15 (t, J=7.1 Hz, 3H). LC/MS (Method B): 512.2 (M+H)+ 510.3 (M−H)−. HPLC (Method A) Rt: 5.27 min (purity: 99%).
후처리
- customThe title compound was prepared following procedure
출처 및 근거
- ORD 기록
- ord-75832f8987294e59affd9fc06eabdb3a
- 출처 데이터셋
- uspto-grants-2012_06
- 특허 번호
- US08202865B2
연결된 노트
불러오는 중…